Reduction of blood pressure to guideline goals (ie,< 130/80 mm Hg) in persons with
diabetes is crucial to optimally reduce cardiovascular events and kidney disease …

National guidelines recommend β‐blockers as second step agents after diuretic therapy in
patients without compelling indications despite little clinical trial evidence of cardiovascular …

In the United States, a vast segment of the adult population is classified as having the
cardiometabolic syndrome, and currently there are epidemic rates of both type 2 diabetes …

Beta blockers have been used in the treatment of cardiovascular conditions for decades.
Despite a long history and status as a guideline-recommended treatment option for …

Beta blockers are frequently used to treat hypertension because of their well established
safety and efficacy. Large clinical trials yield a 12%–20% decline in cardiovascular end …

Hypertension is a risk factor for myocardial infarction (MI), stroke, and heart failure and
precedes heart failure in 91% of cases. This becomes even more important considering that …

Purpose: To review the evidence supporting the “contraindications”(hypoglycemic
unawareness, insulin resistance, and dyslipidemia) usually given as the reasons by …

Hypertension frequently coexists with diabetes and the cardiometabolic syndrome. β‐
Blockers have been a mainstay for controlling blood pressure for nearly 4 decades …

Hypertension is the number one diagnosis made by primary care physicians, placing them
in a unique position to prescribe the antihypertensive agent best suited to the individual …

See original paper on page 1499 b-blocker-based therapy has been a routine treatment for
hypertension for many years. More recently, the effectiveness of b-blocker-based treatment …